The Farmasierra group has launched new forms of vitamin D3 tablets in doses of 1000 IU and 10,000 IU., which add to Vitamin D3 50,000 IU, which is already on sale, and complement Farmasierra’s line of Vitamin D3 tablets, which offers healthcare providers “a range of dosages aimed at providing the appropriate treatment for each patient,” according to the company.
In Spain, data shows low vitamin D levels in 40% of the population under 65 years of age, and this percentage increases to 80% in patients over 65 years of age. Some of the figures will be announced on November 2 as part of World Vitamin D Day to raise awareness of the vital importance of the vitamin and raise awareness of the global epidemic that vitamin D deficiency, or hypovitaminosis, currently poses. D.
Vitamin D deficiency
This vitamin D deficiency is detected in all population groups, both in the general population and, more importantly, in risk groups consisting of individuals who, due to their pathologies, age, lifestyle, need to receive higher doses of vitamin D3 (people obese patients, patients with malabsorption including inflammatory bowel disease and celiac disease, among others).
As Farmasierra explains, cholecalciferol is the most suitable form for the treatment and prevention of vitamin D deficiency due to its specific characteristics, different from those of hydroxylated forms of vitamin D. “Administration of cholecalciferol provides stable levels of vitamin D that are predictable and maintained over time due to its pharmacokinetics. characteristics,” they note.
Indications
The three presentations of the Vitamin D3 Farmasierra line of tablets are products intended to treat hypovitaminosis D, maintain vitamin D levels after treating vitamin D deficiency, or prevent vitamin D deficiency in adults at identified risk.
Another target population is patients receiving osteoporosis medications (antiresorptive or anabolic) who are prescribed vitamin D to maintain serum 25-hydroxycholecalciferol 25(OH)D levels, preferably above 30 ng/mL. “The physician will individualize the dose of vitamin D3 needed to achieve 25(OH)D levels based on patient characteristics, severity of disease, and patient response to treatment,” states the physician. Dr. Begoña Ortiz Santodomingo, Scientific Director of Pharmacierra.
Sample
The pharmacokinetic characteristics of cholecalciferol make it a suitable molecule for daily or intermittent (weekly or monthly) administration of vitamin D. In intermittent treatment, the dose administered is equivalent to the cumulative dose. Research shows that different dosage regimens increase vitamin D levels with similar efficacy and safety. According to Dr. Ortiz, periodic administration is important because it promotes adherence to the treatment regimen;6 in these cases, the duration of treatment should be determined individually by the physician;
As a recommendation for populations with vitamin D3 deficiency, Farmasierra 1000 IU vitamin D3 tablets may be prescribed in doses that may range from 1000 to 4000 IU/day for as long as it takes the patient to achieve adequate 25(OH)D levels. values. . But “according to medical criteria, treatment with Vitamin D3 Farmasierra 10,000 tablets in doses of 10,000–20,000 IU/week for one month may also be appropriate. In both cases, the initial treatment can be followed by maintenance therapy as prescribed by your doctor,” points out Farmasierra’s Scientific Director.
Clinical effectiveness
The clinical effectiveness of cholecalciferol in the treatment and prevention of hypovitaminosis D is supported by extensive and established scientific evidence, according to Pharmacierra, who adds that clinical studies in which anti-osteoporotic drugs have demonstrated high effectiveness in reducing the risk of fractures and have used calcium and vitamin D in the form of cholecalciferol as an adjuvant means. “We developed the vitamin D3 line of products based on national and international clinical guidelines that outline recommendations for the treatment of vitamin D deficiency in both the general population and special populations,” says Dr. Ortiz.